IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4817
Positioning
Market Dominance
Finance, Insurance, And Real Estate
Insurance
$138M
Vijay Kotte
GoHealth, Inc. operates as a health insurance marketplace and Medicare focused digital health company in the United States. The company operates a technology platform that leverages machine-learning algorithms of insurance behavioral data to optimize the process for helping individuals find the health insurance plan for their specific needs. GoHealth sells its products through carriers and online platform, as well as independent and external agencies.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$SII SPROTT INC. | 75 | 91 | 87 | 98 | - | - | 15.7% | 12.8% | 48.9% | 37.0% | 28.8% | 14.9% | 2.5% | 0.0x | $1.1B | VS | |
$PUK PRUDENTIAL PLC | 73 | 88 | 97 | 80 | - | - | 13.2% | 1.4% | 100.0% | 97.0% | 23.8% | 11.8% | 2.7% | 5.0x | $21.5B | VS | |
$NMR NOMURA HOLDINGS INC | 72 | 81 | 92 | 87 | - | - | 9.9% | 0.6% | 84.5% | 70.0% | 7.3% | 14.9% | 0.0% | 923.0x | $18.3B | VS | |
$PSLV Sprott Physical Silver Trust | 69 | 82 | 80 | 98 | - | - | 17.3% | 17.7% | 100.0% | 100.0% | 100.0% | 1643.8% | 0.0% | 0.0x | $5.0B | VS | |
$UFCS UNITED FIRE GROUP INC | 68 | 81 | 93 | 76 | 5.0x | 3.5x | 13.2% | 4.1% | 99.9% | 14.7% | 11.1% | 9.2% | 2.1% | 16.0x | $775M | VS | |
$SLF SUN LIFE FINANCIAL INC | 68 | 83 | 95 | 63 | - | - | 12.6% | 0.9% | 32.0% | 31.3% | 7.9% | -12.9% | 4.3% | 24.0x | $37.8B | VS | |
$CBOE Cboe Global Markets, Inc. | 68 | 75 | 63 | 77 | 21.3x | 15.7x | 24.0% | 13.7% | 41.7% | 32.4% | 26.4% | 8.2% | 1.1% | 30.0x | $25.7B | VS | |
$PHYS Sprott Physical Gold Trust | 67 | 64 | 82 | 91 | - | - | 22.5% | 22.8% | 101.8% | 100.0% | 100.0% | 138.9% | 0.0% | 0.0x | $8.4B | VS | |
$VTMX Vesta Real Estate Corporation, S.A.B. de C.V. | 67 | 69 | 77 | 80 | - | - | 8.8% | 5.8% | 98.7% | 75.7% | 88.5% | 17.6% | 4.3% | 34.0x | $2.2B | VS | |
$GLDM World Gold Trust | 66 | 54 | 85 | 92 | 11.3x | 11.3x | - | 27.1% | 100.0% | 98.9% | 459.9% | 333.4% | 0.0% | 0.0x | $43.7B | VS | |
$GOCO GoHealth, Inc. | 23 | 31 | 27 | 1 | - | - | - | -41.2% | 68.1% | -245.2% | -258.3% | -67.7% | 0.0% | 878.0x | $138M | ||
| SECTOR BENCH | - | - | - | - | - | 11.9x | 7.8x | 8.9% | 1.2% | 76.5% | 17.0% | 21.5% | 10.8% | 1.9% | 0.5x | - | REF |
GoHealth, Inc. (GOCO) receives a "Avoid" rating with a composite score of 23.1/100. It ranks #4817 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Asset base utilization
Financial leverage load
Direct cash return
Vijay Kotte
Chief Executive Officer
Labor Force
5,450
31
36
11
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for GOCO
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Finance, Insurance, And Real Estate sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for GOCO.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 31 | 39 | -8DRAG |
| MOMENTUM | 1 | 0 | +1NEUTRAL |
| VALUATION | 27 | 20 | +7ALPHA |
| INVESTMENT | 36 | 65 | -29DRAG |
| STABILITY | 11 | 6 | +5NEUTRAL |
| SHORT INT | 17 | 4 | +13ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -41.4% vs WACC 3.6% (spread -45.0%)
GM 68% vs sector 77%, OM -245% vs sector 17%
Capital turnover 0.06x
Rev growth -68%, 5yr history
Interest coverage -11.6x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags GoHealth, Inc. with an Avoid rating, assigning a composite score of 23.1/100 and 1 out of 5 stars. Ranked #4817 of 7,333 stocks, GOCO falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
GOCO's quality score of 31/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports gross margins of 68.1% (sector avg: 76.5%), net margins of -258.3% (sector avg: 21.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
GOCO registers a value score of just 27/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 2.02x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
GoHealth, Inc.'s investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -67.7% vs. a sector average of 10.8% and a return on assets of -41.2% (sector: 1.2%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
GoHealth, Inc. is experiencing notably weak momentum with a score of just 1/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -67.7% year-over-year, while a beta of 1.36 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
GoHealth, Inc. registers a low stability score of 11/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.36 and a debt-to-equity ratio of 878.00x (sector avg: 0.5x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
GoHealth, Inc.'s short interest score of 17/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.36), elevated leverage (D/E: 878.00x), micro-cap liquidity risk. At $138M (micro-cap), GOCO carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
GoHealth, Inc. is a micro-cap company in the Finance, Insurance, And Real Estate sector, ranked #0 of 50 in its sector (100th percentile) and #4817 of 7,333 overall (34th percentile). Key comparisons include operating margins of -245.2% below the 17.0% sector average. This top-quartile standing reflects exceptional competitive strength relative to Finance, Insurance, And Real Estate peers.
While GOCO currently exhibits a AVOID profile, superior opportunities exist within the FINANCE, INSURANCE, AND REAL ESTATE sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Finance, Insurance, And Real Estate Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (1) would have the largest impact on the composite score.
Gross Margin 11% BELOW SECTOR MEDIAN
Op. Margin 1541% BELOW SECTOR MEDIAN
Debt/Equity 179084% ABOVE SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate GoHealth, Inc. (GOCO) as Avoid with a composite score of 23.1/100 at a current price of $1.46. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in investment (36th percentile) and quality (31th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (1th percentile) and stability (11th percentile) tempers our overall conviction. We assign a No Moat rating (21/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is narrowing, which raises the risk of a future downgrade if the trend persists.
GoHealth, Inc. holds a top-quartile position (#0 of 50) within the Finance, Insurance, And Real Estate sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 23.1/100 places it at rank #4817 in our full 7,333-stock universe. At $138M in market capitalization, GoHealth, Inc. is a small-cap player in the Finance, Insurance, And Real Estate space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -68% combined with momentum at the 1th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 68% (-8.4pp vs sector) narrow to operating margins of -245% (-262.3pp vs sector) and net margins of -258.3%, yielding a gross-to-net conversion rate of -379%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $1.46, GoHealth, Inc. is trading at a premium to fundamental value. Our value factor score of 27/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 2.0x, P/S of 0.1x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 68% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
The Avoid rating (composite 23.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (878% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Revenue decline of -68% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -258.3% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a Very High uncertainty rating to GoHealth, Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.36), significant leverage (878% debt-to-equity), current negative profitability (net margin -258.3%). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.36); significant leverage (878% debt-to-equity); current negative profitability (net margin -258.3%); below-average price stability (11th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 11th percentile and quality factor at the 31th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 68% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate GoHealth, Inc.'s capital allocation as Poor. Key concerns include elevated leverage (878% D/E), negative profitability, weak asset returns (ROA -41.2%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — GoHealth, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, GoHealth, Inc. receives a Avoid rating with a composite score of 23.1/100 (rank #4817 of 7,333). Our quantitative framework assigns a No Moat (21/100, trend: narrowing), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 21/100.
Our analysis does not support a constructive view on GoHealth, Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign GoHealth, Inc. a meaningful economic moat, scoring 21/100 on our composite assessment. The ROIC-WACC spread of -45.0% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 7.7/20.
The strongest moat sources are margin superiority (7.7/20) and financial resilience (5/20). GM 68% vs sector 77%, OM -245% vs sector 17%. Interest coverage -11.6x. These pillars form the core of GoHealth, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (4.2/20). Capital turnover 0.06x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Narrowing. ROIC has declined at ~6.5pp per year, and operating margins show fundamental deterioration. Investors should monitor these indicators closely — a sustained narrowing trend often precedes material downgrades in our moat assessment.
Key profit drivers include gross margins of 68% providing a solid profitability foundation, declining revenues (-68%) that pressure the earnings outlook. The margin cascade from 68% gross to -245% operating to -258.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 31th percentile.
The margin profile shows gross margins of 68%, operating margins of -245%, net margins of -258.3%. Return metrics include ROA of -41.2%. Relative to the Finance, Insurance, And Real Estate sector, gross margins are 8.4 percentage points below the sector median of 77%.
The balance sheet reflects high leverage with D/E of 878%, which may limit financial flexibility, revenue growth of -68%. The sector median D/E is 0%, putting GoHealth, Inc. at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
Weak momentum (1th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Above 50MA
37.18%
Net New Highs
+51081
The latest update on GoHealth keeps the fair value target steady at 7.7 with the discount rate unchanged at 12.5%, so the core valuation framework remains intact even as expectations around the business are recalibrated. Revenue growth assumptions now reflect roughly a 10.75% decline, which ties back to weaker Q3 trends and the impact of a suspended carrier relationship, while still acknowledging bullish views that tighter cash burn and more disciplined enrollment could create a cleaner base...
Recent updates to GoHealth’s price target are less about a change in the headline fair value, which stays at 7.7, and more about how analysts are thinking about the path the company might take to get there. With the discount rate still at 12.5% and revenue expectations pointing to a slightly smaller 10.75% decline, the latest narrative reflects both the weaker Q3 showing and management’s focus on cash discipline and tighter growth ambitions. As these inputs are refreshed to match new carrier...